We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 03, 2020

Second-Line Lenvatinib in Patients With Recurrent Endometrial Cancer

Gynecologic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Gynecologic Oncology
Second-Line Lenvatinib in Patients With Recurrent Endometrial Cancer
Gynecol. Oncol 2020 Jan 16;[EPub Ahead of Print], I Vergote, MA Powell, MG Teneriello, DS Miller, AA Garcia, ON Mikheeva, M Bidzinski, CL Cebotaru, CE Dutcus, M Ren, T Kadowaki, Y Funahashi, RT Penson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading